The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Weight loss injections could be key to controlling a chronic condition in thousands of Brits, new research suggests ...

A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription ...

India's weight-loss game is getting serious! The country's anti-obesity market is now worth ₹628 crore, and it's climbing ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

Experts reveal how Mounjaro actually works on your body after people took to social media complaining over 'hair loss' side ...

India is stepping into the billion-dollar weight-loss drug war! With Wegovy and Mounjaro already here, Biocon is quietly planning a global disruption with its generic version. Will India’s obesity ...

Weight loss injections like Ozempic, Wegovy, and Mounjaro have revolutionized the obesity fight, helping millions of Americans shed stubborn pounds, lower their blood sugar, and reduce their risk of ...

The marketing makes it sound revolutionary, but here’s the catch: they contain no actual GLP-1 hormone. These aren’t pharmaceutical drugs like Mounjaro or Wegovy.